Endothelial Cell Activation and Thrombin Generation Assessment for the Risk of Severe Early Onset Preeclampsia. the ROADMAP-EOP Study
Background The ROADMAP-EOP study aimed to identify clinically relevant biomarkers of hypercoagulability for the identification of pregnant women at risk of early onset preeclampsia worsening. Methods The ROADMAP-EOP observational single center retrospective case–control study was conducted in Greece...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-11-01
|
| Series: | Clinical and Applied Thrombosis/Hemostasis |
| Online Access: | https://doi.org/10.1177/10760296221138296 |
| _version_ | 1798017392530423808 |
|---|---|
| author | Patrick Van Dreden PhD Eleftheria Lefkou MD, PhD Aboubakar Ka MSc Konstantinos Sfakianoudis MD Aurélie Rousseau PhD Matthieu Grusse MSc Ismail Elalamy MD, PhD Grigoris T Gerotziafas MD, PhD |
| author_facet | Patrick Van Dreden PhD Eleftheria Lefkou MD, PhD Aboubakar Ka MSc Konstantinos Sfakianoudis MD Aurélie Rousseau PhD Matthieu Grusse MSc Ismail Elalamy MD, PhD Grigoris T Gerotziafas MD, PhD |
| author_sort | Patrick Van Dreden PhD |
| collection | DOAJ |
| description | Background The ROADMAP-EOP study aimed to identify clinically relevant biomarkers of hypercoagulability for the identification of pregnant women at risk of early onset preeclampsia worsening. Methods The ROADMAP-EOP observational single center retrospective case–control study was conducted in Greece (Centre for Human Reproduction, Genesis Athens Clinic, Athens, Greece) from July 2020 to July and enrolled pregnant women diagnosed with EOP stratified in mild EOP group (n = 34) and severe EOP group (n = 15) as well as women with uncomplicated pregnancy (control group; n = 35). All women were assessed with thromboelastometry (ROTEM®), Calibrated Automated Thrombogram®, tissue factor activity (TFa), procoagulant phospholipid dependentclotting time (Procoag-PPL®), Proteins S (PS), TFPI, D-dimer, antithrombin (AT), thrombomodulin (TM), fibrinogen, prothrombin time (PT) and activated partial thromboplastin time (aPTT). The primary study end-point was severe earlyonset preeclampsia. Principal component analysis (PCA) was performed. Results The PCA analysis showed that a score composed of the lag-time, ttPeak and Procoag-PPL accurately predicted severe EOP (sensitivity 71.4%, specificity 61.8%, and AUC of the ROC analysis 0.953). Conclusion The pilot ROADMAP-EOP shows that activation of endothelial cells and blood hypercoagulability are driven events in the worsening of EOP. Among a large panel of biomarkers and coagulation assays, thrombingeneration test and procoagulant phospholipid dependent clotting time emerged as clinically relevant for the evaluation of the risk of severe EOP. This methodology for the development of a new clinic-biological risk assessment model for prompt identification of pregnant women at risk of severe EOP must be validated in a large multi-centerprospective study. |
| first_indexed | 2024-04-11T16:05:27Z |
| format | Article |
| id | doaj.art-b287f899fd0e462bae436ca6541fa184 |
| institution | Directory Open Access Journal |
| issn | 1938-2723 |
| language | English |
| last_indexed | 2024-04-11T16:05:27Z |
| publishDate | 2022-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical and Applied Thrombosis/Hemostasis |
| spelling | doaj.art-b287f899fd0e462bae436ca6541fa1842022-12-22T04:14:50ZengSAGE PublishingClinical and Applied Thrombosis/Hemostasis1938-27232022-11-012810.1177/10760296221138296Endothelial Cell Activation and Thrombin Generation Assessment for the Risk of Severe Early Onset Preeclampsia. the ROADMAP-EOP StudyPatrick Van Dreden PhD0Eleftheria Lefkou MD, PhD1Aboubakar Ka MSc2Konstantinos Sfakianoudis MD3Aurélie Rousseau PhD4Matthieu Grusse MSc5Ismail Elalamy MD, PhD6Grigoris T Gerotziafas MD, PhD7 Clinical Research Department, Stago, Gennevilliers, France Perigenesis, Institute of Obstetric Haematology, Thessaloniki, Greece Research Team “Cancer, Angiogenesis, Thrombosis”, Research Group “Cancer, Vessels, Biology and Therapeutics”, Centre de Recherche Saint Antoine (CRSA), INSERM UMR_S 938, Institut Universitaire de Cancérologie, Sorbonne Université, Paris, France Centre for Human Reproduction, Genesis Athens Clinic, Athens, Greece Clinical Research Department, Stago, Gennevilliers, France Clinical Research Department, Stago, Gennevilliers, France Department of Obstetrics and Gynaecology, The First I.M. Sechenov Moscow State Medical University, Moscow, Russia Thrombosis Center, Service d’Hématologie Biologique, Tenon University Hospital, Institut Universitaire de Cancérologie, Assistance Publique - Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, FranceBackground The ROADMAP-EOP study aimed to identify clinically relevant biomarkers of hypercoagulability for the identification of pregnant women at risk of early onset preeclampsia worsening. Methods The ROADMAP-EOP observational single center retrospective case–control study was conducted in Greece (Centre for Human Reproduction, Genesis Athens Clinic, Athens, Greece) from July 2020 to July and enrolled pregnant women diagnosed with EOP stratified in mild EOP group (n = 34) and severe EOP group (n = 15) as well as women with uncomplicated pregnancy (control group; n = 35). All women were assessed with thromboelastometry (ROTEM®), Calibrated Automated Thrombogram®, tissue factor activity (TFa), procoagulant phospholipid dependentclotting time (Procoag-PPL®), Proteins S (PS), TFPI, D-dimer, antithrombin (AT), thrombomodulin (TM), fibrinogen, prothrombin time (PT) and activated partial thromboplastin time (aPTT). The primary study end-point was severe earlyonset preeclampsia. Principal component analysis (PCA) was performed. Results The PCA analysis showed that a score composed of the lag-time, ttPeak and Procoag-PPL accurately predicted severe EOP (sensitivity 71.4%, specificity 61.8%, and AUC of the ROC analysis 0.953). Conclusion The pilot ROADMAP-EOP shows that activation of endothelial cells and blood hypercoagulability are driven events in the worsening of EOP. Among a large panel of biomarkers and coagulation assays, thrombingeneration test and procoagulant phospholipid dependent clotting time emerged as clinically relevant for the evaluation of the risk of severe EOP. This methodology for the development of a new clinic-biological risk assessment model for prompt identification of pregnant women at risk of severe EOP must be validated in a large multi-centerprospective study.https://doi.org/10.1177/10760296221138296 |
| spellingShingle | Patrick Van Dreden PhD Eleftheria Lefkou MD, PhD Aboubakar Ka MSc Konstantinos Sfakianoudis MD Aurélie Rousseau PhD Matthieu Grusse MSc Ismail Elalamy MD, PhD Grigoris T Gerotziafas MD, PhD Endothelial Cell Activation and Thrombin Generation Assessment for the Risk of Severe Early Onset Preeclampsia. the ROADMAP-EOP Study Clinical and Applied Thrombosis/Hemostasis |
| title | Endothelial Cell Activation and Thrombin Generation Assessment for the Risk of Severe Early Onset Preeclampsia. the ROADMAP-EOP Study |
| title_full | Endothelial Cell Activation and Thrombin Generation Assessment for the Risk of Severe Early Onset Preeclampsia. the ROADMAP-EOP Study |
| title_fullStr | Endothelial Cell Activation and Thrombin Generation Assessment for the Risk of Severe Early Onset Preeclampsia. the ROADMAP-EOP Study |
| title_full_unstemmed | Endothelial Cell Activation and Thrombin Generation Assessment for the Risk of Severe Early Onset Preeclampsia. the ROADMAP-EOP Study |
| title_short | Endothelial Cell Activation and Thrombin Generation Assessment for the Risk of Severe Early Onset Preeclampsia. the ROADMAP-EOP Study |
| title_sort | endothelial cell activation and thrombin generation assessment for the risk of severe early onset preeclampsia the roadmap eop study |
| url | https://doi.org/10.1177/10760296221138296 |
| work_keys_str_mv | AT patrickvandredenphd endothelialcellactivationandthrombingenerationassessmentfortheriskofsevereearlyonsetpreeclampsiatheroadmapeopstudy AT eleftherialefkoumdphd endothelialcellactivationandthrombingenerationassessmentfortheriskofsevereearlyonsetpreeclampsiatheroadmapeopstudy AT aboubakarkamsc endothelialcellactivationandthrombingenerationassessmentfortheriskofsevereearlyonsetpreeclampsiatheroadmapeopstudy AT konstantinossfakianoudismd endothelialcellactivationandthrombingenerationassessmentfortheriskofsevereearlyonsetpreeclampsiatheroadmapeopstudy AT aurelierousseauphd endothelialcellactivationandthrombingenerationassessmentfortheriskofsevereearlyonsetpreeclampsiatheroadmapeopstudy AT matthieugrussemsc endothelialcellactivationandthrombingenerationassessmentfortheriskofsevereearlyonsetpreeclampsiatheroadmapeopstudy AT ismailelalamymdphd endothelialcellactivationandthrombingenerationassessmentfortheriskofsevereearlyonsetpreeclampsiatheroadmapeopstudy AT grigoristgerotziafasmdphd endothelialcellactivationandthrombingenerationassessmentfortheriskofsevereearlyonsetpreeclampsiatheroadmapeopstudy |